

Effects of anti-osteoporosis treatment in elderly patients with osteoporosis and lumbar discectomy and fusion

Tao Shi*, Fenyong Shou, Qun Xia, Tao Zhang, Donghui Teng, Wanli Jing and Qiang Zhou

Department of Orthopedics, School of Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China

Received 17 November 2023

Accepted 17 March 2024

Abstract.

BACKGROUND: The effect of anti-osteoporosis treatment in elderly patients with osteoporosis and lumbar discectomy and fusion (LIF) for lumbar degenerative diseases is not well known.

OBJECTIVE: This study aimed to evaluate the effect of perioperative anti-osteoporosis treatment in the patients with osteoporosis and LIF.

METHODS: From January to December 2022, patients were divided into three groups according to the inclusive criteria: the normal group (Group A), the osteopenia group (Group B) and the osteoporosis group (Group C). Quantitative computed tomography (QCT), height of the intervertebral space (HIS), segmental sagittal angle (SSA), visual analogue scale (VAS) score and Oswestry Disability Index (ODI) were compared between the groups at the follow-up time. The serum Ca^{2+} , osteocalcin (OC), propeptide of type I procollagen (PINP) C-terminal cross-linking telopeptide of type I collagen (β -CTX) and 25-OH vitamin D (25-OH V_D) levels were compared between the groups at the time of follow-up. Interbody fusion was graded on the X-ray and CT images at the follow-up time.

RESULTS: There were 165 patients in this study. There were significant differences in the mean age, mean score, HIS and SSA between the groups at the different follow-up times. There were significant differences in the concentrations of serum Ca^{2+} , OC, β -CTX, 25-OH V_D and PINP at the sixth month after surgery between the groups. There were significant differences in the concentrations of serum Ca^{2+} , β -CTX and 25-OH V_D between the pre-surgery and at six months after surgery in Group B and β -CTX and 25-OH V_D in Group C. There was a significant difference in the degree of fusion between Group B and C ($\chi^2 = 5.6243$, $P < 0.05$).

CONCLUSION: In elderly patients with LIF and osteoporosis, anti-osteoporosis therapy could reduce bone resorption and thus facilitate fusion. Anti-osteoporosis medication tends to enhance radiological, functional, and fusion short-term outcomes.

Keywords: Elderly patients, degenerative lumbar disease, lumbar discectomy and fusion, osteoporosis, anti-osteoporosis

1. Introduction

Posterior lumbar interbody fusion (PLIF) and transforaminal lumbar interbody fusion (TLIF) with seg-

mental pedicle screws are common procedures for treating lumbar degenerative disorders that relieve pain and enhance function [1,2]. However, as more people experience spinal fusion, the number of fusion-related problems has risen [3,4]. There have been reports of adjacent vertebral body fractures caused by rigid pedicle screw fixation [5,6]. The reason for this is that arthrodesis may modify spinal kinematics, resulting in relative hypermobility of spinal segments next to the fused level [7,

*Corresponding author: Tao Shi, Department of Orthopedics, School of Medicine, Tianjin First Central Hospital, Nankai University, No. 24 Fukang Road, Nankai District, Tianjin 300192, China. E-mail: shitaostone@163.com.

8]. This alteration in segmental spinal biomechanics could lead to a higher rate of vertebral compression fractures (VCFs). Especially among elderly patients, osteoporosis further increases fracture risk.

After spinal fusion surgery, rigid spinal instrumentation can cause device-related osteoporosis of the fused segment, as well as a decrease in the bone mineral density (BMD) of adjacent vertebrae, which can contribute to adjacent level VCFs [9,10,11]. Moreover, osteoporosis increases the risk of fractures in elderly individuals. The decrease in BMD could be due to immobilization or to changes in biomechanics caused by arthrodesis. However, the mechanism of BMD loss after spinal fusion surgery, is yet unknown. Zoledronic acid (ZA) has been shown to be an effective osteoporosis treatment in postmenopausal women in several studies, as it significantly reduces the risk of vertebral, hip, and other fractures [12]. Additionally perioperative ZA treatment may offer protection against a significant decrease in the BMD of cephalad vertebrae after spinal fusion surgery among postmenopausal women with osteoporosis [13].

Denosumab is a biological product that blocks the RANK ligand (RANKL)-mediated activation of osteoclasts. It has been demonstrated to be useful in treating osteoporosis [14], with effectiveness comparable to that of bisphosphonate [15]. However, to our knowledge, no previous study has evaluated the effect of denosumab on the change in the BMD of the adjacent vertebral body after instrumented intervertebral fusion, fusion time, or operation. As a result, the goal of this study was to determine whether denosumab can increase the BMD of the adjacent vertebral body after spinal surgery while also improving the fusion time and outcome of the operative segment.

2. Methods

2.1. Study design

This study was conducted from January to December 2022. The study protocol was approved by the Ethics Committee of Tianjin First Central Hospital (approval ID: 2022N122KY).

Written informed consent was obtained from all study participants and confidentiality of information was assured.

2.2. Study patients

The medical records of consecutive patients admitted for lumbar degenerative diseases (LDDs), including

lumbar disc herniation (LDH) with instability, lumbar spinal stenosis (LSS), degenerative spondylolisthesis (DSI), isthmic spondylolisthesis (IS) and degenerative scoliosis (DS) to the hospital from January to December 2022 were collected.

Inclusion criteria: 1) X-ray, computed tomography (CT) and quantitative computed tomography (QCT, Siemens Edge, the measuring software was QCT Pro from Midways, www.QCT.com) and magnetic resonance imaging (MRI) results were obtained; 2) Serum Ca^{2+} , osteocalcin (OC), propeptide of type I procollagen (PINP) C-terminal cross-linking telopeptide of type I collagen (β -CTX) and 25-OH Vitamin D (25-OH V_D) results were obtained; 3) other blood test results were normal; 4) patients underwent PLIF or TLIF; 5) the follow-up results were intact; 6) no operative complications; 7) osteoporosis was defined by $\text{BMD} < 80 \text{ mg/cm}^3$ and $\text{T score} < -2.5$, osteopenia was defined by $80 \text{ mg/cm}^3 < \text{BMD} < 120 \text{ mg/cm}^3$ and $-2.5 < \text{T score} < -1$, and normal defined by $\text{BMD} > 120 \text{ mg/cm}^3$ and $\text{T score} > -1.0$ were on QCT measures obtained before surgery; 8) patients underwent follow-up QCT evaluation at 6–12 months after surgery.

Exclusion criteria: 1) required intervertebral fusion of > 3 levels; 2) had a prior history of lumbar surgery and required lumbar surgery during the follow-up period; 3) had no lumbar disorders that may affect bone metabolism, such as cancer, infection or trauma; 4) those with osteoporosis secondary to various metabolic diseases, such as thyroid or parathyroid disease, and other endocrine diseases; 5) required use of a lumbar brace for > 2 months after surgery; 6) had any disability that limited the patient's walking ability for > 1 week during the follow-up period; and 7) smoked and(or) had sarcopenia. The patients were divided into three groups: Group A included normal patients; Group B included patients with osteopenia and Group C included patients with osteoporosis.

2.3. Surgical procedure

All patients underwent PLIF or TLIF. A posterior midline incision was made and the posterior elements of the spine were exposed. After pedicle screw insertion, a medial facetectomy was performed. Then the nerve root was mobilized medially to access the disc space. In the TLIF procedure, the superior and inferior articular processes of the facet joint are resected and the disc in the neuroforamen is exposed. After removal of the disc and scraping of the endplates, the anterior part of the disc space is packed with autologous bone chips. The




Fig. 1. HIS before and after surgery.




Fig. 2. SSA before and after surgery.

disc space is measured by trial insertion of variously sized spacers and a sizeable cage is inserted. All patients were asked to use a lumbar brace while walking for 4–6 weeks after surgery.

2.4. Imaging parameters

HIS was measured via X-ray before surgery, after surgery and at the last follow-up (Fig. 1). The HIS was the average of the anterior and posterior HISs at the same intervertebral space. SSA was measured via X-ray before surgery, after surgery and at the last follow-up (Fig. 2).

2.5. Bone metabolic markers

Serum Ca^{2+} , OC, PINP β -CTX and 25-OH V_D were tested before surgery and at the sixth month after surgery.

2.6. Anti-osteoporosis treatment

The anti-osteoporosis treatments used were 1200 mg/day oral calcium, 800IU/day activated vitamin D and 60 mg subcutaneous injection of denosumab every 6 months for the patients in Group C. Denosumab (American Amgen Inc.) was injected on the sixth day after surgery when the incision was not swollen and exuding. The treatment for patients in Group B was 1200 mg/day oral calcium and 800IU/day activated vitamin D.

2.7. Clinical treatment assessment

The VAS and ODI scores were assessed before the operation, after the operation and at the last follow-up. Interbody fusion was graded on the X-ray by the

108
109
110
111
112
113
114
115
116
117
118
119
120
121
122

123
124
125
126
127
128
129
130
131
132
133
134
135
136

Table 1
Demographic characteristic of 165 patients with LIF (n-165)

Characteristics	Group A (n = 52)	Group B (n = 62)	Group C (n = 51)	P
Mean age(yr)	50.7 ± 7.3	66.0 ± 4.5	69.1 ± 6.4	< 0.01
Sex, M/F	13/39	12/50	2/49	
Follow-up duration (month)	10.7 ± 0.2	10.8 ± 0.3	10.8 ± 0.2	> 0.05
Fusion level				
1 level	30	25	19	
2 levels	20	25	20	
3 levels	2	12	12	
Total	76	111	95	
Mean level	1.5 ± 0.6	1.8 ± 0.7	1.9 ± 0.8	< 0.05




Fig. 3. According to Mayer's research, Grade 3, Grade 2 and Grade 1 were identified at the sixth month after surgery (from left to right).

method of Brantigan and Steffee [16] as modified to describe the Fraser definition of locked pseudarthrosis (BSF scale) [17] at the third month and last follow-up after surgery. Interbody fusion by CT was performed as described by Mayer et al. [18] at the sixth month after surgery (Fig. 3). According to the CT results of Mayer et al. the definite fusion is Grade 1 or Grade 2.

2.8. Statistical analysis

Variables were compared among the three groups using one-way ANOVA and *t* tests for several parameters preoperatively and at the sixth month after surgery. *P* value < 0.05 was considered to indicate statistical significance. All statistical analyses were performed using SPSS software version 11.0 (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. Demography

There were 165 patients in this study including 52 patients in Group A, 62 in Group B and 51 in Group C. Table 1 displays the mean age, follow-up duration, and sex and fusion level of the different groups. There were

significant differences in the mean age ($P < 0.01$) and mean level ($P < 0.05$), but not at the follow-up.

3.2. Imaging parameters

Table 2 displays the preoperative, postoperative and last follow-up HIS and SSA. There were significant differences in the HIS among the three groups ($P < 0.05$) and among the different follow-up times ($P < 0.01$). Table 3 displays the QCT and T score results before the operation and at the sixth month after surgery. There were significant differences in the BMD and T score among the three groups at the same follow-up time ($P < 0.01$) and between the Group B ($P < 0.05$) and C ($P < 0.05$) at the different follow-up times.

3.3. Bone metabolic markers

Table 4 shows the serum Ca^{2+} , OC, PINP, β -CTX and 25-OH V_D levels before surgery and at the sixth month after surgery in the three groups. There were significant differences in the concentrations of serum Ca^{2+} , OC, β -CTX, 25-OH V_D and PINP at six months after surgery among the three groups. Between pre-operation and six months after surgery, there were significant differences in the concentrations of serum Ca^{2+} , β -CTX and 25-OH V_D in Group B, β -CTX and 25-OH V_D in Group C.

Table 2
Comparison of image parameters between different groups ($n = 165$)

	Group A ($n = 52$)	Group B ($n = 62$)	Group C ($n = 51$)	P
Preoperative HIS (mm)	7.9 ± 2.0	8.9 ± 2.5	9.0 ± 2.7	< 0.05
Postoperative HIS (mm)	10.9 ± 1.8	11.5 ± 1.9	11.9 ± 2.2	< 0.05
Last follow-up HIS (mm)	10.5 ± 1.8	10.9 ± 1.7	11.8 ± 2.3	< 0.01
P	< 0.01	< 0.01	< 0.01	
Preoperative SSA ($^{\circ}$)	15.6 ± 7.7	16.3 ± 9.2	17.4 ± 7.3	> 0.05
Postoperative SSA ($^{\circ}$)	18.8 ± 8.0	20.5 ± 8.5	21.3 ± 7.8	> 0.05
Last follow-up SSA ($^{\circ}$)	18.7 ± 5.0	19.8 ± 9.3	21.3 ± 8.5	> 0.05
P	< 0.05	< 0.01	< 0.01	

HIS: Height of intervertebral space; SSA: segmental sagittal angle.

Table 3
Comparison of QCT results between different groups ($n = 165$)

	Group A ($n = 52$)	Group B ($n = 62$)	Group C ($n = 51$)	P
BMD (g/cm^3)				
Pre-operation	138.8 ± 9.9	108.2 ± 18.5	64.7 ± 18.8	< 0.01
At the sixth month	137.5 ± 9.2	99.1 ± 17.9	72.1 ± 11.2	< 0.01
P	> 0.05	< 0.05	< 0.05	
T score				
Pre-operation	1.3 ± 0.1	-2.1 ± 0.3	-2.9 ± 0.3	< 0.01
At the sixth month	1.3 ± 0.1	-2.2 ± 0.2	-2.7 ± 0.2	< 0.01
P	> 0.05	< 0.05	< 0.01	

BMD: Bone mineral density.

Table 4
Comparison of bone metabolic markers results between different groups ($n = 165$)

	Group A ($n = 52$)	Group B ($n = 62$)	Group C ($n = 51$)	P
Serum Ca^{2+} (mmol/L)				
Preoperative	2.3 ± 0.1	2.3 ± 0.1	2.2 ± 0.1	< 0.01
At the sixth month after surgery	2.3 ± 0.1	2.2 ± 0.1	2.2 ± 0.2	< 0.01
P	> 0.05	< 0.01	> 0.05	
OC (ng/ml)				
Preoperative	21.8 ± 3.7	18.3 ± 4.1	16.3 ± 9.5	< 0.01
At the sixth month after surgery	22.9 ± 3.9	18.1 ± 3.3	17.8 ± 8.2	< 0.01
P	> 0.05	> 0.05	> 0.05	
PINP (ng/ml)				
Preoperative	42.3 ± 6.2	39.1 ± 10.8	40.7 ± 20.7	> 0.05
At the sixth month after surgery	43.5 ± 6.8	37.7 ± 9.9	41.8 ± 18.8	< 0.05
P	> 0.05	> 0.05	> 0.05	
β -CTX (ng/ml)				
Preoperative	0.3 ± 0.1	0.5 ± 0.2	0.6 ± 0.3	< 0.01
At the sixth month after surgery	0.3 ± 0.1	0.6 ± 0.1	0.5 ± 0.1	< 0.01
P	> 0.05	< 0.01	< 0.05	
25-OH V_D (ng/ml)				
Preoperative	37.8 ± 4.2	15.8 ± 6.6	16.7 ± 7.1	< 0.01
At the sixth month after surgery	36.9 ± 3.9	18.3 ± 5.8	27.3 ± 2.1	< 0.01
P	> 0.05	< 0.05	< 0.01	

OC: Osteocalcin; PINP: Propeptide of type I procollagen; β -CTX: C-terminal cross-linking telopeptide of type I collagen; 25-OH V_D : 25-OH Vitamin D.

3.4. Fusion assessment

Table 5 shows the X-ray results for the BSF at the third month and last follow-up after surgery and Mayer Grade results on the CT scan at the sixth month after surgery. According to the BSF scale, the prevalence of BSF-3 was 94.2% in Group A, 90.3% in Group B and

92.3% in Group C. Grade 1 and Grade 2 were defined according to Mayer's grade and were 96.2% in Group A, 64.5% in Group B and 78.4% in Group C. There was a significant difference in the percentage of patients with definite fusion between Groups B and C ($\chi^2 = 5.6243$, $P < 0.05$). The X-ray results were the same result at the last follow-up. The definite fusion in the

182
183
184
185
186
187

188
189
190
191
192
193
194

Table 5
Comparison of interbody fusion results between different groups ($n = 165$)

	Group A ($n = 52$)	Group B ($n = 62$)	Group C ($n = 51$)	P
X-ray assessment				
Third month after surgery				
BSF-1		6	3	
BSF-2	35	48	41	
BSF-3	17	8	7	
Last follow-up after surgery				
BSF-1		3	1	
BSF-2	3	3	2	
BSF-3	49	56	48	
CT assessment				
Sixth month after surgery				
Grade 1	47	21	19	
Grade 2	3	19	24	
Grade 3	2	16	6	
Grade 4		6	2	
VAS				
Pre-operation	6.8 ± 0.3	6.8 ± 0.2	6.9 ± 0.3	> 0.05
Post-operation	2.2 ± 0.2	3.3 ± 0.3	3.4 ± 0.2	< 0.01
Last follow-up	0.8 ± 0.1	1.3 ± 0.4	1.1 ± 0.1	< 0.01
P	< 0.01	< 0.01	< 0.01	
ODI				
Pre-operation	66.2 ± 8.5	69.2 ± 10.3	70.1 ± 11.0	> 0.05
Post-operation	32.9 ± 7.1	35.8 ± 7.1	36.2 ± 8.3	> 0.05
Last follow-up	8.3 ± 3.7	11.7 ± 6.1	10.9 ± 5.8	< 0.01
P	< 0.01	< 0.01	< 0.01	

VAS: visual analogue scale; ODI: Oswestry Disability Index.

Table 6

Comparison of interbody fusion results of the different diseases according to CT assessment ($n = 165$)

	LDH	LSS	DSI	IS	DS
Grade 1	66	11	2	7	1
Grade 2	24	14	1	6	1
Grade 3	2	3	7	5	6
Grade 4			2	2	4

LDH: lumbar disc herniation with instability; LSS: lumbar spinal stenosis; DSI: degenerative spondylolisthesis; IS: isthmic spondylolisthesis; DS: degenerative scoliosis.

different diseases was LDH, followed by LSS, and the fusion rates were lower for DSI and DS (Table 6).

3.5. Clinical treatment assessment

The VAS and ODI scores before surgery, after surgery and at the last follow-up are displayed in the Table 5. There were significant differences in VAS and ODI scores between the same group at the different follow-up times and among the three groups at the last follow-up time. At the sixth month after surgery, Fig. 4 shows a typical case in Group A, Fig. 5 displays a typical case in Group B and Fig. 6 shows a typical case in Group C. Figure 7 displays the screw pedicle cut out and fusion failure at the third month after surgery in Group B.

4. Discussion

Osteoporosis is a silent killer of human health and a major public health concern. In 2006 there were approximately 70 million osteoporotic patients and more than 200 million patients with osteopenia in China [19]. According to previous research, Asians have a lower bone mass than Caucasians and Afro-Caribbeans [20]. LDH, LSS, DSI, IS and DS are common LDDs that occur mostly in elderly patients and need LIF for treatment. In elderly individuals, the osteoporosis and LDD often coexist. Osteoporosis, a degenerative disease characterized by bone loss and structural deterioration, is the most common challenge of LIF. The main cause of osteoporosis in women is menopause, while aging is main cause in men, and is also the main cause of osteopenia.

To restore spinal stability and decompress nerves in elderly patients with LDD and osteoporosis, there have been some reports about the use of cement-augmented pedicle screw fixation to restore spinal stability [21, 22], but these complications may be fatal [23,24]. One study revealed that the strong pedicle screw fixation could be achieved by increasing the BMD around the screw and prevent fatal complication, this treatment involved anti-osteoporosis treatment during the spinal surgery and the follow-up period [25]. In our study, one patient with osteopenia, spondylolisthesis and lumbar




Fig. 4. Female patient, 52 yrs, lumbar spondylolisthesis and lumbar disc herniation before surgery, and normal patient. PLIF was carried out. At the sixth month after surgery the interbody fusion was Grade 1 according to Mayer's research. The trabeculae were filled with interbody space.




Fig. 5. Female patient, 63 years old, with lumbar spondylolisthesis and lumbar disc herniation before surgery; osteoporosis; PLIF; oral calcium 1200mg/day; activated vitamin D 800IU/day before and after surgery. At the sixth month after surgery, the interbody fusion was Grade 3 according to Mayer's research. The red arrows show the unfused areas; and the trabeculae exhibited a palisade pattern.

235 disc herniation underwent PLF, but at the third month
 236 after surgery, the screw pedicle was cut out, the reduction
 237 effect on lumbar spondylolisthesis was lost, and
 238 fusion failed. This patient had no other uncomfortable
 239 symptoms except for mild low back pain and was still
 240 being followed up. Anti-osteoporosis agents have been
 241 shown to result in strong pedicle screw fixation with
 242 an increase in the BMD around the screw, but there
 243 have been few reports about the effectiveness of anti-
 244 osteoporosis agents for fusion of LIF. Our study focused
 245 on the short-term effect of LIF fusion during the spinal
 246 surgery in combination with denosumab for preventing
 247 osteoporosis.

In this study, the HIS and SSA were greater at the
 248 last follow-up than at the pre-operation, which demon-
 249 strated that the LIF could increase the HIS and improve
 250 lumbar lordosis. In the osteopenia group the HIS and
 251 SSA at the last follow-up were lower than those at the
 252 post-operation, but not in the osteoporosis group. Ac-
 253 cording to some studies patients with low lumbar BMD
 254 may have a relatively high incidence of interbody fusion
 255 cage-related complications; for example, sinking
 256 of the interbody fusion cage may lead to gradual nar-
 257 rowing of the HIS, which affects anterior support of the
 258 spine and prevents successful fusion [26]. Several re-
 259 searchers have shown that BMD is related to the stable
 260 failure load of the endplate and cage [27,28]. Addition-
 261




Fig. 6. Female patient, 66 years old, with lumbar spondylolisthesis and lumbar disc herniation before surgery; osteoporosis; PLIF; oral calcium 1200mg/day; and activated vitamin D 800IU/day before and after surgery. Denosumab was injected at the sixth day after surgery. At the sixth month after surgery, the interbody fusion was Grade 2 according to Mayer's research. The red arrows show the unfused area, which was just a small area, and the other areas were fused.




Fig. 7. Female patient, 67 yrs, with lumbar spondylolisthesis and lumbar disc herniation before surgery; osteopenia; PLIF; oral calcium 1200mg/day; and activated vitamin D 800IU/day before and after surgery. At the third month after surgery, the screw pedicle was cut out; and fusion failure occurred.

262 ally the correlation between the BMD and subsidence
 263 was very weak, and patients with a score < -3.0 had
 264 an increased risk of subsidence [29]. Cho et al. reported
 265 that the sedimentation rate was higher in the patients
 266 with the T score ≤ -2.5 than in the patients with the T
 267 score ≥ -1.0 [30]. In our study, the subsidence of the
 268 HIS in the osteopenia group was greater than that in the
 269 osteoporosis group because anti-osteoporosis treatment
 270 was used in the osteoporosis group.

271 In our study the serum Ca^{2+} and 25-OH V_D concen-
 272 trations were greater at six months after surgery than be-

273 fore surgery in the osteopenia and osteoporosis groups,
 274 which proves the 1200 mg/day calcium and 800IU/day
 275 activated vitamin D 8 was necessary for patients with
 276 osteopenia or osteoporosis. There was little change in
 277 the bone formation markers including the OC and PINP
 278 in the osteopenia and osteoporosis groups, but there was
 279 a high variability in the bone resorption marker, which
 280 is the β -CTX index in the osteopenia and osteoporosis
 281 groups. The β -CTX increased at the sixth month after
 282 surgery in the osteopenia group, but decreased in the
 283 osteoporosis group due to the use of anti-osteoporosis

284 drugs. This finding also proved that denosumab could
285 inhibit the activity of osteoclasts.

286 The VAS and ODI scores were improved at the last
287 follow-up compared to the pre-operation. At six months
288 after surgery the rate of definite fusion in the osteo-
289 porosis group were greater than that in the osteopenia
290 group. The incidence of osteopenia and osteoporosis
291 was lower than the normal group. According to these
292 studies, the fusion rates were different after treatment
293 with different anti-osteoporosis drugs; for example, one
294 year after surgery, the fusion rate was 95% in the alen-
295 dronate group [31], but the rate of bone fusion tended to
296 be greater in the weekly teriparatide group than in the
297 bisphosphonate group at the sixth month after surgery
298 (46.8% vs. 32.7%) [32]. One study showed that alen-
299 dronate does not influence the fusion process in osteo-
300 porotic patients, and in alendronate group, fusion was
301 achieved in 66.7% of patients compared to 73.9% of
302 patients in control group (no medication) [33]. The fu-
303 sion rate was greater in the osteoporosis group than in
304 the osteopenia group, but this difference was detected at
305 only the sixth month according to the QCT. There were
306 three typical cases from three groups: in the normal
307 group the trabeculae fill the intervertebral space and
308 fusion was complete at the sixth month after surgery;
309 but in the osteopenia group the shape of trabeculae was
310 like palisade, there was no trabeculae growth at some
311 areas and lack of bone support, fusion effect was poor at
312 the sixth month after surgery; in the osteoporosis group
313 there was also lack of trabeculae at some areas which
314 were smaller than in the osteopenia group and no shape
315 of palisade area, and the fusion effect was better than
316 the osteopenia group and worse than normal group.

317 Denosumab is an anti-resorptive agent with a novel
318 mechanism of action [34,35] and a fully human mono-
319 clonal antibody that binds RANKL, preventing RANKL
320 from activating RANK, its receptor on the osteo-
321 clast surface [35]. Reducing RANK-RANKL binding
322 inhibits osteoclast formation, function, and survival,
323 which results in a decrease in bone resorption and an
324 increase in bone mass [35,36,37]. The mechanism of
325 action of denosumab is different from that of bisphos-
326 phonates. The mechanism of action of bisphosphonates
327 includes: 1) a strong affinity for bone embedding in
328 the bone mineral, and crossing cell membranes when
329 osteoclasts resorb the bone matrix; 2) clearance from
330 the circulation via renal excretion or adsorption to bone
331 minerals, but bone-associated drugs must first be re-
332 leased by osteoclast-mediated bone resorption; and 3)
333 residue in the bone for a period of weeks to years. The
334 mechanism of action of denosumab includes: 1) not

embedding within bone tissue, binding to RANKL in
335 the extracellular fluid and circulation, and inhibiting
336 osteoclast formation, function and survival; 2) clearing
337 from the bloodstream through the reticuloendothelial
338 system; and 3) maintaining a half-life of approximately
339 26 days and not inducing the formation of neutralizing
340 antibodies.

341 The follow-up time varied according to the detection
342 type. Bone metabolic markers were detected at the sixth
343 month after surgery due to injection of denosumab ev-
344 ery 6 months. X-ray imaging was carried out at the third
345 and sixth month to assess the degree of facet joint fu-
346 sion. QCT was assessed at the sixth month to determine
347 the degree of interbody fusion. The detections were
348 carried out as little as possible to avoid unnecessary
349 radiation and pain, except for necessary tests.

350 This study has several limitations. First, the follow-
351 up time in this study was relatively short, but we think
352 that follow-up time was long enough for patients to
353 preliminarily recover, at which time all patients needed
354 to complete interbody fusion after surgery. However, a
355 prospective study with a larger sample size and longer
356 term follow up should be conducted in the future. Sec-
357 ond, this was a single-center-study, and the sample size
358 was small. A multicenter study will be ideal. In ad-
359 dition, the study lacked detailed classification of pa-
360 tients with osteoporosis due to deficiencies in related
361 detection methods.

362 5. Conclusions

363 In elderly patients with LIF and osteoporosis anti-
364 osteoporosis therapy could reduce bone resorption and
365 thus facilitate fusion. Anti-osteoporosis medication
366 tends to enhance radiological, functional, and fusion
367 short-term outcomes. The anti-osteoporosis treatment
368 should also be advocated for patients with LIF and os-
369 teopenia.

370 Acknowledgments

371 The authors are grateful for the support of the Osteo-
372 porosis Innovation Award Fund of the Chinese Associ-
373 ation of Medical Education.

374 Author contributions

375 T.S.: initial idea, wrote and revised manuscript and
376 acquired funding. F.Y.S.: data collection, editing and
377

378 statistical analysis. X.Q.: methodology. T.Z.: data col-
379 lection. T.D.H.: data collection. W.L.J.: data collection.
380 Q.Z.: data collection. All authors read and approved the
381 final manuscript.

382 Conflict of interest

383 The authors declare that they have no conflict of
384 interest.

385 Data availability statement

386 The datasets used and/or analyzed in this study are
387 available from the corresponding author on reasonable
388 request.

389 Ethics approval

390 Ethical approval was obtained from the Committee
391 for Medical Ethics of Tianjin First Central Hospital
392 (2022N122KY).

393 Funding

394 This study was supported by the Osteoporosis In-
395 novation Award Fund of the Chinese Association of
396 Medical Education (2022-011).

397 Informed consent

398 Written informed consent was obtained from all
399 study participants and confidentiality of information
400 was assured.

401 References

- 402 [1] Gertzbein SD, Betz R, Clements D, Errico T, Hammerberg K,
403 Robbins S, et al. Semirigid instrumentation in the management
404 of lumbar spinal conditions combined with circumferential fu-
405 sion. A multicenter study. *Spine (Phila Pa 1976)*. 1996; 21(16):
406 1918-1925. doi: 10.1097/00007632-199608150-00018.
- 407 [2] Wang JC, Mummaneni PV, Haid RW. Current treatment strate-
408 gies for the painful lumbar motion segment: posterolateral
409 fusion versus interbody fusion. *Spine (Phila Pa 1976)*. 2005;
410 30(16 Suppl): S33-S43. doi: 10.1097/01.brs.0000174559.
411 13749.83.
- 412 [3] Machado GC, Maher CG, Ferreira PH, Harris IA, Deyo RA,
413 McKay D, et al. Trends, complications, and costs for hospi-
414 tal admission and surgery for lumbar spinal stenosis. *Spine*
415 *(Phila Pa 1976)*. 2017; 42(22): 1737-1743. doi: 10.1097/BRS.
416 0000000000002207.

- 417 [4] Rometsch E, Spruit M, Zigler JE, Menon VK, Ouelle JA, 418
Mazel C, et al. Screw-related complications after instrumen- 419
tation of the osteoporotic spine: a systematic literature review 420
with meta-analysis. *Global Spine J*. 2020; 10(1): 69-88. doi: 421
10.1177/2192568218818164. 422
- 423 [5] Chiu Y-C, Tsai T-T, Yang S-C, Chen H-S, Kao Y-H, Tu Y-K. 424
Impact of instrumented spinal fusion on the development of 425
vertebral compression fracture. *Medicine (Baltimore)*. 2016; 426
95(17): e3455. doi: 10.1097/MD.0000000000003455. 427
- 428 [6] Li Y-C, Yang S-C, Chen H-S, Kao Y-H, Tu Y-K. Impact of lum- 429
bar instrumented circumferential fusion on the development of 430
adjacent vertebral compression fracture. *Bone Joint J*. 2015; 431
97-B(10): 1411-1416. doi: 10.1302/0301-620X.97B10.34927. 432
- 433 [7] Axelsson P, Johnsson R, Stroinqvist B. The spondylyolytic 434
vertebra and its adjacent segment. Mobility measured before 435
and after posterolateral fusion. *Spine (Phila Pa 1976)*. 1997; 436
22(4): 414-417. doi: 10.1097/00007632-199702150-00012. 437
- 438 [8] Bastian L, Lange U, Knop C, Tusch G, Blauth M. Evalua- 439
tion of the mobility of adjacent segments after posterior thora- 440
columbar fixation: a biomechanical study. *Eur Spine J*. 2001; 441
10(4): 295-300. doi: 10.1007/s005860100278. 442
- 443 [9] Bogdanffy GM, Ohnmeiss DD, Guyer RD. Early changes in 444
bone mineral density above a combined anteroposterior L4-S1 445
lumbar spinal fusion. A clinical investigation. *Spine (Phila 446
Pa 1976)*. 1995; 20(15): 1674-1678. doi: 10.1097/00007632- 447
199508000-00005. 448
- 449 [10] Lipscomb HJ, Grubb SA, Talmage RV. Spinal bone density 450
following spinal fusion. *Spine (Phila Pa 1976)*. 1989; 14(4): 451
477-479. doi: 10.1097/00007632-198904000-00028. 452
- 453 [11] Balci A, Kalemci O, Kaya FG, Akyoldas G, Yucesoy K, Ozak- 454
soy D. Early and long-term changes in adjacent vertebral body 455
bone mineral density determined by quantitative computed 456
tomography after posterolateral fusion with transpedicular 457
screw fixation. *Clin Neurol Neurosurg*. 2016; 145: 84-88. doi: 458
10.1016/j.clineuro.2016.04.014. 459
- 460 [12] Reid DM, Devogelaer J-P, Saag K, Roux C, Lau C-S, Re- 461
ginster J-Y, et al. Zoledronic acid and risedronate in the pre- 462
vention and treatment of glucocorticoid-induced osteoporosis 463
(HORIZON): a multicentre, double-blind, double-dummy, ran- 464
domised controlled trial. *Lancet*. 2009; 373(9671): 1253-1263. 465
doi: 10.1016/S0140-6736(09)60250-6. 466
- 467 [13] Fan J, Liu T, Dong X, Sun S, Zhang H, Yang C, et al. Effect of 468
Zoledronic Acid on the Vertebral Body Bone Mineral Density 469
After Instrumented Intervertebral Fusion in Postmenopausal 470
Women With Osteoporosis. *Global Spine Journal*. 2023; 13(5): 471
1280-1285. doi: 10.1177/21925682211027833. 472
- 473 [14] Cummings SR, Martin JS, McClung MR, Siris ES, Eastell 474
R, Reid IR, et al. Denosumab for prevention of fractures in 475
postmenopausal women with osteoporosis. *New England Jour- 476
nal of Medicine*. 2009; 361(8): 756-65. doi: 10.1056/NEJ- 477
Moa0809493. 478
- 479 [15] Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Grego- 480
rio LH, et al. Comparison of the effect of denosumab and al- 481
endronate on BMD and biochemical markers of bone turnover 482
in postmenopausal women with low bone mass: a randomized, 483
blinded, phase 3 trial. *Journal of Bone & Mineral Research*. 484
2009; 24(1): 153-61. doi: 10.1359/jbmr.0809010. 485
- 486 [16] Brantigan JW, Steffee AD. A carbon fiber implant to aid in- 487
terbody lumbar fusion. Two-year clinical results in the first 26 488
patients. *Spine (Phila Pa 1976)*. 1993; 18(14): 2106-2107. doi: 489
10.1097/00007632-199310001-00030. 490
- 491 [17] Santos ERG, Goss DG, Morcom RK, Fraser RD. Radiologic 492
assessment of interbody fusion using carbon fiber cages. *Spine 493
(Phila Pa 1976)*. 2003; 28(10): 997-1001. doi: 10.1097/01. 494

- 481 BRS.0000061988.93175.74.
- 482 [18] Siepe CJ, Stosch-Wiechert K, Heider F, Amnajtrakul P, Kre- 527
 483 nauer A, Hitzl W, et al. Anterior stand-alone fusion revisited: 528
 484 a prospective clinical, X-ray and CT investigation. *Eur Spine* 529
 485 *J.* 2015; 24(4): 838-851. doi: 10.1007/s00586-014-3642-y. 530
- 486 [19] Chinese health promotion foundation editorial board of Chinese 531
 487 White Papers of osteoporosis (2009) Chinese White Papers of 532
 488 osteoporosis. *Chin J Health Manag.* 3: 148-154. 533
- 489 [20] Mittal S, Kumar A, Gupta RK, Kapoor S, Gulati P, Shukla 534
 490 DK. Comparison of bone mineral density and its variables 535
 491 between premenopausal and postmenopausal women. *J Obstet* 536
 492 *Gynaecol India.* 2011; 61: 200-204. doi: 10.1007/s13224-011- 537
 493 0024-9. 538
- 494 [21] Kanno H, Onoda Y, Hashimoto K, Aizawa T, Ozawa H. Rein- 539
 495 forcement of Percutaneous Pedicle Screw Fixation with Hy- 540
 496 droxyapatite Granules in Patients with Osteoporotic Spine: 541
 497 Biomechanical Performance and Clinical Outcomes. *Medicina* 542
 498 (Kaunas). 2022; 58(5): 579. doi: 10.3390/medicina58050579. 543
- 499 [22] Amendola L, Gasbarrini A, Fosco M, Simoes CE, Terzi S, De 544
 500 lure F, et al. Fenestrated pedicle screws for cement-augmented 545
 501 purchase in patients with bone softening: a review of 21 cases. 546
 502 *J Orthopaed Traumatol.* 2011; 12(4): 193-199. doi: 10.1007/ 547
 503 s10195-011-0164-9. 548
- 504 [23] Zhang J, Wang G, Zhang N. A meta-analysis of complica- 549
 505 tions associated with the use of cement-augmented pedicle 550
 506 screws in osteoporosis of spine. *Orthopaedics & Traumatol- 551
 507 ogy: Surgery & Research.* 2021; 107(7): 102791. doi: 10.1016/ 552
 508 j.otsr.2020.102791. 553
- 509 [24] Morimoto T, Kobayashi T, Hirata H, Tsukamoto M, Yoshihara 554
 510 T, Toda Y, et al. Cardiopulmonary Cement Embolism Follow- 555
 511 ing Cement-Augmented Pedicle Screw Fixation: A Narrative 556
 512 Review. *Medicina (Kaunas).* 2023; 59(2): 407. doi: 10.3390/ 557
 513 medicina59020407. 558
- 514 [25] Tani S, Ishikawa K, Kudo Y, Tsuchiya K, Matsuoka A, 559
 515 Maruyama H, et al. The effect of denosumab on pedicle screw 560
 516 fixation: a prospective 2-year longitudinal study using finite 561
 517 element analysis. *Journal of Orthopaedic Surgery and Research.* 562
 518 2021; 16(1): 219. doi: 10.1186/s13018-021-02360-2. 563
- 519 [26] Fukuta S, Miyamoto K, Hosoe H, Shimizu Katsuji. Kidneytype 564
 520 intervertebral spacers should be located anteriorly in cantilever 565
 521 transforaminal lumbar interbody fusion: analyses of risk fac- 566
 522 tors for spacer subsidence for a minimum of 2 years. *Journal* 567
 523 *of Spinal Disorders & Techniques.* 2011; 24(3): 189-195. doi: 568
 10.1097/BSD.0b013e3181e9f249. 569
- 524 [27] Hou Y, Yuan W. Influences of disc degeneration and bone min- 570
 525 eral density on the structural properties of lumbar end plates. 571
 526 *The Spine Journal.* 2012; 12(3): 249-256. doi: 10.1016/j. 572
 spinee.2012.01.021. 573
- [28] Jones C, Okano I, Salzmann SN, Reisener M-J, Chiapparelli 574
 E, Shue J, et al. Endplate volumetric bone mineral density 575
 is a predictor for cage subsidence following lateral lumbar 576
 interbody fusion: a risk factor analysis. *The Spine Journal.* 577
 2021; 21(10): 1729-1737. doi: 10.1016/j.spinee.2021.02.021. 578
- [29] Oh KW, Lee JH, Lee J-H, Lee D-Y, Shim HJ. The correlation 579
 between cage subsidence, bone mineral density, and clinical 580
 results in posterior lumbar interbody fusion. *Clinical Spine* 581
Surgery. 2017; 30(6): E683-E689. doi: 10.1097/BSD.0000000000000315. 582
- [30] Cho JH, Hwang CJ, Kim H, Joo Y-S, Lee D-H, Lee CS. Ef- 583
 fect of osteoporosis on the clinical and radiological outcomes 584
 following one-level posterior lumbar interbody fusion. *Journal* 585
of Orthopaedic Science. 2018; 23(6): 870-877. doi: 10.1016/j. 586
 jos.2018.06.009. 587
- [31] Stone MA, Jakoi AM, Iorio JA, Pham MH, Patel NN, Hsieh 588
 PC, et al. Bisphosphonate's and Intermittent Parathyroid Hor- 589
 mone's Effect on Human Spinal Fusion: A Systematic Review 590
 of the Literature. *Asian Spine J.* 2017; 11(3): 484-493. doi: 591
 10.4184/asj.2017.11.3.484. 592
- [32] Oba H, Takahashi J, Yokomichi H, Hasegawa T, Ebata S, 593
 Mukaiyama K, et al. Weekly Teriparatide Versus Bisphos- 594
 phonate for Bone Union During 6 Months After Multi-Level 595
 Lumbar Interbody Fusion for Osteoporotic Patients. *Spine* 596
(Phila Pa 1976). 2020; 45(13): 863-871. doi: 10.1097/BRS. 597
 00000000000003426. 598
- [33] Kim SM, Rhee W, Ha S, Lim JH, Jang IT. Influence of al- 599
 endronate and endplate degeneration to single level posterior 600
 lumbar spinal interbody fusion. *Korean J Spine.* 2014; 11(4): 601
 221-226. doi: 10.14245/kjs.2014.11.4.221. 602
- [34] Belavic JM. Denosumab (Prolia): a new option in the treatment 603
 of osteoporosis. *Nurse Pract.* 2011; 36(1): 11-12. doi: 10.1097/ 604
 01.NPR.0000391178.47878.73. 605
- [35] Prolia Product Monograph. Amgen Canada Inc, October 2011. 606
- [36] Lipton A, Goessl C. Clinical development of anti-RANKL 607
 therapies for treatment and prevention of bone metastasis. 608
Bone. 2011; 48(1): 96-99. doi: 10.1016/j.bone.2010.10.161. 609
- [37] Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, 610
 Yang Y-C, et al. Effects of denosumab treatment and discontin- 611
 uation on bone mineral density and bone turnover markers in 612
 postmenopausal women with low bone mass. *J Clin Endocrinol* 613
Metab. 2011; 96(4): 972-980. doi: 10.1210/jc.2010-1502. 614